DanCann Pharma A/S

Hjem
Danmark
Ansager
DanCann Pharma A/S

DanCann Pharma A/S
- a biopharmaceutical company powered by cannabinoids Lad os holde den gode tone 😊

Om DanCann Pharmas Facebook:

Alle er velkomne til at kommentere på opslag her på siden, hvis det foregår på et sagligt niveau i god ro og orden. Vi forbeholder os ret til uden varsel at fjerne opslag eller kommentarer, som er stødende eller i et uacceptabelt sprog. Ligeledes forbeholder vi os ret til at udelukke brugere, som ikke overholder ovenstående retningslinjer.

27/10/2023

DanCann Pharma A/S announces news regarding its new strategic direction for the future.

Read the press release below, where the market is addressed, and the company's future prospects are discussed and guided.

COPENHAGEN, Denmark, 26 October 2023 – DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann

02/10/2023

DanCann Pharma A/S will provide a comprehensive update on its new strategy and growth plans in October.

COPENHAGEN, Denmark, 02 October 2023 – DanCann Pharma A/S, DanCann Pharma A/S (SS: DANCAN) (OTCQB:

31/08/2023

DanCann Pharma A/S to refocus its strategy - will reinvigorate its pipeline and product portfolio, and start looking for future owner or partnership for BP1

COPENHAGEN, Denmark, 31 August 2023 – DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann

17/07/2023

DanCann Pharma A/S has successfully received the first tranche of DKK 6.6 million from the 10-year financing loan agreement with Nordic Growth Opportunities 2.

COPENHAGEN, Denmark, 17 July 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma"

02/06/2023

DanCann Pharma A/S is pleased to announce to the market and its investors that it has successfully entered into an agreement with a new investor for a total of DKK 18.9 million, which complements the TO 2 warrants, resulting in a total of approximately DKK 24.5 million before expenses.

COPENHAGEN, Denmark, 02 June 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma"

02/06/2023

DanCann Pharma A/S receives approximately DKK 5.6 million from the exercise of series TO 2 together with a directed issue to the underwriters.

COPENHAGEN, Denmark, 02 June 2023 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "

01/06/2023

DanCann Pharma A/S' Pre-Validation Batches Meets European Standards, paving the Path for Final Product Approval

COPENHAGEN, Denmark, 01 June 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma"

31/05/2023

Today, DanCann Pharma A/S has released its Q1-2023 Report.

COPENHAGEN, Denmark, 31 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma"

30/05/2023

DanCann Pharma A/S: MINUTES OF ANNUAL GENERAL MEETING

held in DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”) Tuesday, 30 May 2023 at 09:00 am (

26/05/2023

DanCann Pharma A/S has secured 71 percent of the TO 2’s

COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma"

26/05/2023

DanCann Pharma A/S has successfully completed pre-validation batches and expects final approval from the Danish Medicines Agency by the end of summer

COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma"

26/05/2023

DanCann Pharma A/S in advanced talks with new investor of additional DKK 12 million for topping up the outcome of the TO 2’s

COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma"

Adresse

Rugvænget 6
Ansager
6823

Internet side

http://dancann.com/

Underretninger

Vær den første til at vide, og lad os sende dig en email, når DanCann Pharma A/S sender nyheder og tilbud. Din e-mail-adresse vil ikke blive brugt til andre formål, og du kan til enhver tid afmelde dig.

Kontakt Virksomheden

Send en besked til DanCann Pharma A/S:

Genveje

Vil du plassere din virksomhed på toppen av Ingeniørvirksomhed-listen i Ansager?

Del

Type

Bioteknologisk virksomhed